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The use of lipid-based nanoparticles for the delivery of bio-macromolecules has attracted 
considerable attention due to the current interest in protein-based therapeutics. Cubosomes 
protect the incorporated therapeutics, which are susceptible to degradation by enzymes, 
thereby improving their bioavailability, and concomitantly enhance cellular uptake. The 
cubosome nanoparticles presented herein were loaded with bovine serum albumin (BSA), and 
characterized by small angle X-ray scattering and dynamic light scattering techniques, while 
the BSA encapsulation and its release were evaluated in vitro. The ability of this formulation 
to increase by two fold the cellular uptake of low-molecular-weight (LMW) tracers was tested 
on various types of renal tubular cells, and confirmed by in vivo renal uptake experiments in 
mice. Obtained results show that cubosomes are able to deliver BSA inside the cell through a 
distinct intracellular routing. Even in state of genetically-driven disruption of receptor 
mediated endocytosis, the BSA uptake is increased irrespective of the genetic background and 
its degradation in lysosomes delayed. These data were substantiated in vivo, with evidence of 
high cubosome-mediated uptake of BSA in wildtype mice and in Clcn5y/- mice characterized 
by defective receptor-mediated endocytosis. 
The use of cubosomes as a delivery system able to overcome the low endocytic uptake in 








An ideal drug delivery system (DDS) should be stable and biocompatible, incorporate the 
active agent without loss or alteration of its activity, provide an efficient delivery to specific 
location in vivo, and also show optimal cellular uptake and clearance pathways, thereby 
enhancing the in vivo efficiency of the drug 1, 2. Cellular uptake and efficient release at its 
target location are the first challenges to consider when designing nanocarriers as DDS. The 
nanoparticle can enter the cell via an endocytic pathway; however the endocytosed 
nanoparticles should be able to escape endosomal entrapment before formation of acidic late 
endosomes in addition to resist clearance via endocytic recycling and exocytosis 3. 
Controlling endosomal release is therefore crucial in the design of nanoparticles for efficient 
drug delivery.  
The size and the shape of nanoparticles are critical factors to control cellular uptake 4. 
Specifically, for lipid-based nanoparticles, the membrane properties and the particle’s internal 
structure have a key role in cellular drug delivery efficiency 5. Lipidic mesophases (LMPs) 
composed by monoolein (MO) show a higher endosomal escape, precisely the escape from 
late endosomes to avoid lysosomal degradation, in mammalian cell culture when compared to 
parent Lipoplex systems 6. The LMP’s membrane is able to efficiently escape from 
endosomal entrapment by lowering the free energy cost of forming pores in endosomal 
membranes. LMPs are similar in consistency and rheology to cross-linked polymeric 
hydrogels. However, these bulk phases that lack colloidal stability are not suitable in a 
systemic administration that requires a stable nanoscale particulate system.  
Cubosomes, the water-dispersed form of the lipidic cubic phase, possess an identical 
microstructure to that of the parent gel phase, but exhibit a much lower viscosity in 
comparison to the bulk phase 7. Such dispersions are commonly prepared by mixing 
monoolein (MO) and water in appropriate proportions, and are stabilized by using a poly 
(ethylene oxide) −poly (propylene oxide) −poly (ethylene oxide) block copolymer 8. 
Compared with the parent gels, dispersions exhibit improved fluidity and larger surface area, 
thereby providing various means of potential formulations 9. The use of cubosomes for the 
delivery of bio-macromolecules has attracted considerable attention due to the current interest 
in protein-based therapeutics 10, 11. Many studies have shown that the thermal stability and 
activity of proteins are retained within a cubic phase matrix. Moreover, the structure of lipidic 
cubic phase represents an ideal medium for the encapsulation of soluble and integral 
membrane proteins ranging in size from lysozyme (14 kDa 12) to fibrinogen (340 kDa 13).  
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The epithelial cells lining the proximal tubules (PT) of the kidney constitute a paradigm 
of effective communication between the external environment and the endomembrane system, 
allowing to reabsorb a large amount of filtered ions and solutes. By processing incoming 
substances and recycling receptors and transporters at the apical plasma membrane, the 
connecting endolysosomal system dictates the terminal differentiation of the cells, and hence 
the recovery and processing of essential substances that would otherwise be lost in the urine 
14. In particular, the reabsorption of albumin and low-molecular-weight (LMW) proteins from 
the glomerular filtrate occurs via receptor-mediated endocytosis in PT cells. This process is 
initiated by the binding of ligands to the receptors megalin and cubilin, followed by their 
internalization through clathrin-coated pits and processing in the endolysosomes 15. In genetic 
and acquired kidney disorders this process is disrupted, causing massive loss of solutes in the 
urine resulting in life-threatening complications 16-19. A paradigm of defective receptor-
mediated endocytosis is Dent disease, caused by inactivating mutations in the CLCN5 gene 
coding for the endosomal chloride-proton exchanger ClC-5. Investigations using the well-
established Clcn5 knock-out mouse model of Dent disease have demonstrated that the disease 
is caused by a generalized trafficking defect, with loss of apical megalin and cubilin receptors, 
leading to the massive urinary loss of albumin and LMW solutes 14, 16. The uptake of albumin 
and LMW tracers is routinely investigated in various cellular systems modelizing PT cells, 
characterized by variable levels of differentiation and endocytic uptake capacity 20.   
  
The goal of this study was to probe the potential of cubosome nanoparticles as a 
biocompatible and non-toxic delivery system to overcome the deficient receptor-mediated 
endocytic activity in the renal proximal tubule. Colloidally stable cubosome nanoparticles 
composed of MO and loaded with labeled bovine serum albumin (BSA) are presented in this 
study. The cubosomes were characterized by small angle X-ray scattering and dynamic light 
scattering techniques. The uptake of the cubosome-BSA formulation was tested in vitro on 
different PT cell models and confirmed by in vivo experiments in Clcn5 mice. These data 
constitute the first in vivo application of cubosomes, which are able to overcome a clinically-





Chemicals and reagents 
1-Monooleoyl-sn-glycerol C18: 1 (monoolein, MO) was purchased from Nu-Chek Prep, Inc. 
(MN, USA), phosphate buffer solution (PBS (1X) pH 7.4), BSA from Bovine Serum (BSA) 
Alexa Fluor® 488 conjugate and BSA Alexa Fluor® 647 conjugate were purchased from 
Invitrogen. Pluronic® F-127 (PF127), BSA was purchased from Sigma Aldrich. All solutions 
were prepared using Mill-Q water (18.2MΩ cm−1; Millipore, Bedford, MA). Conjugate BSA-
Gold 10nm was purchased from BBITM solutions (Cardiff, UK). 
 
Preparation of cubosomes 
Cubosomes (empty, loaded with BSA Alexa Fluor® 488 conjugate, BSA Alexa Fluor® 647 
conjugate, Conjugate BSA-Gold or BSA) were prepared as described by Murgia et al. 21. 
Briefly, a solution of the appropriate amount of MO in CHCl3 was evaporated to provide a 
film of MO on the wall of a round-bottom flask. A solution of stabilizer (PF127) in PT cell 
medium was added to the preformed films after overnight storage in a desiccator under 
reduced pressure (0.4 mbar) to yield the cubosome solution with the desired lipid 
concentration. The solution was vortex-mixed and then dispersed using an ultrasonic 
processor Brenson digital 250 (cycle 0.9s on/ 0.9s off, amplitude 50%, for 10min). 
Subsequently, the cubosome dispersion was filtered through Acrodisc 450nm. The 
concentrations of MO and stabilizer in the resulting dispersions were typically 0.150mg/mL 
and 0,0136mg/mL, respectively. For the BSA-loaded cubosomes, an aliquot of BSA solution 
in PBS (5mg/mL) was added to a vial with dry MO in order to obtain the appropriate amount 
of BSA after hydration. The lipid and protein mixture was then processed as described 
previously.  
 
Dynamic light scattering (DLS) 
Particle size and z-potential determination of the cubosomes were performed immediately 
after preparation, and one week later (while the aggregate size was checked every day) with a 
Zeta Sizer Nano ZS (Malvern Instruments, Malvern, UK) at 37 ± 0.1°C. The samples were 
housed in disposable polystyrene cuvettes of 1 cm optical path length with water as solvent. 
Scattering angle was 90°. At least three independent samples were taken, each of which was 
measured between three to five times. The width of the DLS hydrodynamic diameter 
distribution is indicated by PDI (polydispersion index). The intensity size distribution of the 
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cubosomes was typically unimodal; therefore the autocorrelation function was analyzed 
according to the cumulant method.  
 
Small angle X-ray scattering (SAXS) 
SAXS measurements were used to determine the symmetry and unit cell dimensions of the 
cubosomes (33mg/mL MO and 0.3mg/mL PF127) under various conditions. Experiments 
were performed either on the empty cubosomes or on the loaded cubosomes (the molar ratio 
of BSA to lipid is 1:280, which is identical to the ratio used in the experiments with the cells) 
using a microfocused Rigaku X-ray source of wavelength λ = 1.54Å, operating at 45kV and 
88 mA. Scattered X-ray signal was detected with a gas-filled two-dimensional (2D) detector. 
The scattering vector q = (4π/λ)sin θ, with 2θ being the scattering angle, was calibrated using 
silver behenate. The sample-to-detector distance was 1m, providing a q range from 0.005 to 
0.77Å-1. Data were collected and azimuthally averaged using the Saxsgui software to yield 1D 
intensity versus scattering vector q. Samples were loaded into a quartz glass capillary 
(Hiligenberg, length: 80mm; outside: 2.0mm; wall thickness: 0.01mm). Measurements were 
performed at 37°C, and samples were equilibrated for 10min prior to measurements, while 
scattered intensity was collected over 10 hours. A mathematical model was used to calculate 
the structural parameter of the Im3m phases. Briefly, following determination of the lattice 
parameter by SAXS, and assuming a fixed lipid volume fraction, and a constant geometry of 




Excess non-incorporated BSA (BSA Alexa Fluor® 488 conjugate, and BSA Alexa Fluor® 
647 conjugate and Gold-BSA) were separated from the cubosomes by dialysis as follows: 
About 5mL of sample was placed in the Spectra/Por membrane (300KDa cut off; Spectrum 
Laboratories Inc., USA) and dialyzed against water (500mL) for 48h at 25°C. The 
encapsulation efficiency (E%) of BSA (BSA Alexa Fluor® 488 conjugate, and BSA Alexa 
Fluor® 647 conjugate) entrapped in cubosomes after dialysis was established by 
spectrofluorometry (with Infinite® 200 Tecan) and calculated using equation 1. The amount of 
BSA (in mg/mL) entrapment in the formulation was determined by using a calibration curve. 
 




Where Fbefore and Fafter are the fluorescence values of BSA in the cubosomes before and after 
dialysis. 
The amount of BSA (BSA Alexa Fluor® 488 conjugate, and BSA Alexa Fluor® 647 
conjugate and Conjugate BSA-Gold 10nm) entrapped in cubosomes after the dialysis was 
additionally confirmed by a standard PierceTM BCA protein assay (Thermo Fisher, Scientific).  
 
Release experiments 
Following removal of the free (un-entrapped) protein, the cubosomes were transferred to a 
new dialysis tube at 7 consecutive time points (after 1, 2, 3, 4, 5, 6 and 7 days). Immediately 
before loading the sample into the tube (T0), an aliquot of cubosomes (100 mL) was removed 
from the dialysis tube and analyzed spectrofluorimetrically. All measurements were 
performed at 37°C. The percentage of Alexa Fluor® BSA release was determined by equation 
2 and plotted versus time. 
 
% Release = 100 - (Ft/ F0 ×100)       Eq. 2 
 
Where Ft and F0 are the values of fluorescence at times t and 0, respectively, i.e. before 
loading the sample.  
 
Fluorescence quenching experiments 
Fluorescence quenching experiments on a solution of BSA dissolved in PBS, and on BSA 
entrapped in cubosomes were performed before and after dialysis treatment using iodide (I-) 
as collisional quencher. All fluorescence experiments were carried out at 37°C on solutions 
with optical densities smaller than 0.05 to minimize inner filter effects. Fluorescence 
quenching experiments were performed by adding small aliquots of 0.1 M I- (containing small 
amount of Na2S2O4 to avoid the oxidation of the quencher) solution to the samples 23. The 
concentrations of the lipid and BSA were 0.150mg/mL and 0.1mg/mL, respectively. Decrease 
of the fluorescence of the BSA Alexa Fluor® 488 conjugate was monitored at 526nm by 
exciting at 480nm.  
 
Fluorescence anisotropy 
Fluorescence Anisotropy experiments on a solution of the BSA Alexa Fluor® 488 conjugate 
dissolved in PBS or entrapped in cubosomes, before and after dialysis treatment were 
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performed. Anisotropy measurements were collected using an L-format configuration, and all 
data were corrected for polarization bias using the G-factor. Low-volume quartz cuvettes with 
an optical path length of 1.0 × 0.2cm were used to reduce the scattering effects from the 
cubosome solutions. The concentration of the MO and BSA were 0.150mg/ mL and 0.1mg/ 
mL respectively.  
 
Proximal tubule cell types and culture conditions 
Immortalized human kidney cells, HK2 (ATCC, Teddington, UK) were cultured in 
endothelial growth medium (DMEM F-12, 21041-025, Life technology) supplemented with 
EGM single quots (Lonza, CC-4133). The immortalized opossum kidney, OK, cells (ATCC, 
Teddington, UK) were cultured in DMEM (Gibco; Life Technologies, Paisley, UK) 
containing 10% FCS (Gibco; Life Technologies, Paisley, UK). Cells were grown on chamber 
slides (Falcon, VWR) or 96 well plates until confluent 20. 
Differentiated, polarized mouse primary PT cells were obtained after micro-dissection of 
mouse kidney cortex and cultured as previously described 17. 
 
MTT assay (Cell Counting Kit-8, Dojindo Laboratories, Kumamoto, Japan).  
Cells were seeded on 96-well cell culture plates (Nunc, Thermo Scientific, Roskilde, 
Denmark) and treated with Cyclohexylamine (CHA, Sigma-Aldrich, Steinheim, DE) once 
they were confluent. After incubation with CHA, 10µl of CCK-8 solution (Dojindo 
Laboratories, Kumamoto, Japan) was added to the well and incubated for 4h at 37°C. 
Subsequently, the absorbance at 450nm was determined using an Infinite M200 Pro TECAN 
spectrophotometer (Tecan, Männedorf, Switzerland). Equal numbers of untreated cells were 
used as controls 20. 
 
Cubosome treatment in vitro. Cells were grown until confluent and then starved with serum-
free medium to reduce background signal through maintenance turnover. The cells were 
pulsed with cubosome solution for 1h at 4°C. Three different sample preparations were used: 
pure Alexa Fluor® BSA (0.1mg/ml), pure Alexa Fluor® BSA (0.1mg/ml) mixed with empty 
cubosomes (150µg/ml) and with cubosomes (150µg/ml) loaded with Alexa Fluor® BSA 
(0.1mg/ml), respectively to directly compare the influence of the cubosome nanoparticles on 




Time course experiment and inhibition. Cells were grown until confluent and subsequently 
starved with serum-free medium to reduce background signal through maintenance turnover. 
Confluent chamber slides were then pulsed with cubosome samples for 1h at 4°C, with 
subsequent degradation monitored at t=0, 5min, 15min, 60min. Metabolic inhibition was 
achieved by 10mM NaN3/ 50mM DOG (Sigma) and lysosomal block was obtained using 
250mM Bafilomycin respectively 17. For both inhibitions the agents remained in the medium 
through the whole process.  
 
Immunostaining. After cubosome incubation, cells were fixed for 10min at -20°C in ice-cold 
methanol (Methanol purum, UZH, Zurich, Switzerland). After 3x5min washing in PBS, 
30min blocking at room temperature was performed in PBS (Gibco; Life Technologies, 
14040-091) supplemented with 5%FBS and 1% Triton-X-100 (Sigma Aldrich, Steinheim, 
DE, 9284). Incubation with primary antibodies, diluted in antibody dilution buffer (PBS, 1% 
BSA (VWR, 421501J), 1% Triton-X-100) was done for 2-3h at room temperature. The cells 
were then washed 3x5min in PBS and incubated with secondary antibody (diluted 1:200 in 
antibody dilution buffer) for 1h at room temperature in the dark. After 3x5min washing in 
PBS, the slides were mounted with ProLong® Gold with Dapi (Life Technologies) and stored 
at 4°C until analysis. 
The following antibodies were used for immunostaining: Rab5 (Abcam, ab18211), Rab7 
(Abcam, ab137029), CatD (Santa Cruz, sc-7486). 
 
Microscopy.  
Confocal Microscopy: CLSM Leica SP5 Mid UV-VIS/ resonant. Picture processing and 
analysis was done using Imaris Software 7.6.3. 
Electron microscopy. 150µg/ml cubosomes were loaded with 100 µg/ml BSA-gold and 
incubated for 1h at 37°C on confluent cells. Cells were then first fixed with 2.5% 
glutaraldehyde (Sigma Aldrich) in 0.1M cacodylate buffer for 1 hour at 37°C and sequentially 
treated with 1% OsO4 for 1 hour at 0°C and 2% uranyl acetate in nanopure water for 1h at 
4°C. The cells were dehydrated in an ethanol series and embedded in Epon/Araldite (Sigma-
Aldrich). Ultrathin (50 nm) sections were contrasted with lead citrate and examined with a 
CM100 transmission electron microscope (FEI, Eindhoven, The Netherlands) at an 
acceleration voltage of 80 kV using an Orius 1000 digital camera (Gatan, Munich, Germany).  
 
Cubosome treatment in vivo.  
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Experiments were conducted on male knock-out (Clcn5Y/-) and wild-type (Clcn5Y/+) 
littermates (C57BL/6 background 16). Mice were maintained under temperature-and humidity-
controlled conditions with 12-h light/12-h dark cycles with free access to appropriate standard 
diet in accordance with the institutional guidelines of National Institutes of Health Guide for 
the Care and Use of Laboratory Animals. The protocols were approved by the Animal Ethics 
Committees of the University of Zurich.  
Mice (Clcn5Y/- vs. wild-type) were anaesthetized with inhaled isoflurane (Attane, Provet AG, 
Switzerland) in 100 ml/min Oxygen. For dye application the internal jugular vein was 
cannulated (PE10 tubing), the left kidney was externalized for imaging and the mouse was 
mounted on a custom-built temperature-controlled holder specially designed to reduce 
movement artefacts. Imaging was performed on a custom-built microscope as described by 
Mayrhofer 24 and Schuh 25. 250µl of the cubosome or control solution (both containing 
0.1mg/ml BSA) was injected with a 500µl Hamilton glass syringe (model 1750TLLX, 
Hamilton) at a rate of 300 µl/minute. Imaging was performed at a rate of 1 frame/10 sec. 
After frame 6 (1 min) the automated syringe pump (pump 11 elite nanomite, Havard 
apparatus) was activated. For the time series analysed a total of 80 frames were recorded, the 
intensity changes were analysed in FIJI (imageJ). For general analysis ROI squares (15 x 
15px) were placed on the nephron or the vasculature. As raw data 32 signal positive nephron 
segments (PTs) were chosen (only 19 in CLC5 BSA since not more positive nephron 
segments found), their mean intensity over time (80 fr) was exported to excel 2013 and the 
mean +/- SEM was visualized with graphpad prism. The images for Fig. 6 were exported as 
single frame after 11 min recording with Imaris (Bitplane, vs. 7.7.2). The resolution is 1024 x 
1024px and all images were adjusted to the settings (minimum 0, maximum 2500 & gamma 
1). The images were exported as grayscale in 12 bit with 600 dpi (tiff) and the movie files 
were generated with Imaris and recorded as avi with 1024 x 1024 px, no compression and 10 
frames per second. 
 
Statistical analysis  
Data were expressed as mean ± SEM. Significance of differences was assessed by unpaired 




Characterization of the cubosome aggregates  
The final concentrations of MO and PF127 in the cubosome dispersions were typically 0.150 
and 0.0136 mg/mL, respectively. SAXS experiments were performed on empty and BSA-
loaded cubosomes (Table 1; Fig.1A).  
 
Figure 1. Cubosome preparation 
(A) SAXS spectra of empty and BSA-loaded cubosomes. (B) % of BSA in the dialysis tube plotted versus time. BSA solution in 
PBS, and BSA loaded in cubosomes are shown as black and white circles, respectively. The inset shows the calibration curve 
of BSA Alexa Fluor® 488 conjugate (black circles) and the amount of BSA Alexa Fluor® 488 conjugate in cubosomes after 
dialysis (white circle). Data are expressed as mean ± SD from three independent experiments. (C) Fluorescence quenching 
experiments by I- of: BSA solution in PBS (white circles), BSA incorporated in cubosomes before and after dialysis treatment 
(black circles and triangles, respectively). Mean ± SD (n=3). (D) Percentages of BSA release (black circles) from the 
aqueous compartments of the cubosomes as a function of time (left axis) and size measurement (black diamonds, right axis) 
as a function of time. Mean ± SD (n=3). 
Table 1. Samples, mean diameter (Dav), Polydispersity index (PDI), ζ-potential (z-pot), phase identity (P.I), 
crystallographic unit cell parameters (a) and water channel diameter (dw) observed for the cubosome nanoparticles. 
Sample Dav (nm) PDI ζ-pot (mV) P.I. a (Å) dw (Å) 
Empty  
BSA-Loaded  
139 ± 4 
142 ± 2 
0.08±0.01 
 0.09 ± 0.02 
- 25.8 ± 0.5 








MO dispersions in PF127 constitute a well-known system, and the phase diagram of the 
ternary MO/water/PF127 system is reported 26. In agreement with the literature, addition of 
PF127 to the system induces a cubic-Pn3m to cubic-Im3m phase transition 27. Interestingly, 
12 
 
addition of the soluble protein BSA, at the level used, does not affect the phase identity and 
the lattice parameter (see Table 1) of the MO/H2O/PF127 system 5, 28, which is Im3m 
throughout, with a unit cell parameter of 134.8 Å. The cubosomes used in this study - empty 
and loaded with BSA - show larger aqueous channel diameters (48.8 Å and 48.4 Å, 
respectively) as compared with cubosomes of Pn3m symmetry 22, whose aqueous channel 
diameters range in size between 35 and 40 Å 21. Moreover, as summarized in Table 1, 
incorporation of the BSA does not alter the size and the z-potential of the aggregates 29. 
 
Efficacy of BSA entrapment  
Excess of non-incorporated BSA was removed from the cubosomes by dialysis as reported in 
the experimental section. The amount of BSA loaded in cubosomes after the dialysis was 
analyzed spectrofluorimetrically and determined using a calibration curve. When a BSA 
solution in PBS (0.5 mg/mL) was loaded into the dialysis tube, the entire protein content can 
diffuse trough the membrane tube, and hence no protein was detected in the tube after 48 
hours (black circles Fig. 1B). In contrast, when BSA (0.5 mg/mL) is incorporated in the 
cubosomes, 20 % of the protein (white circle Fig. 1B), corresponding to 0.1 mg/mL of BSA 
are firmly entrapped in the cubosome after the same dialysis treatment (marked as a white 
circle in the inset of Fig. 1B). The amount of BSA loaded in the cubosomes was also 
confirmed by protein quantification assay, as described in the experimental section. 
 
Location of BSA and release from cubosome structures 
Fluorescence anisotropy and quenching measurements provide independent confirmation that 
BSA is embedded in the aqueous channels of the cubosome. Solutions of BSA Alexa Fluor® 
488 dissolved in PBS, and BSA Alexa Fluor® 488 entrapped in cubosomes (final 
concentration of BSA is 0.1 mg/mL) were subjected to fluorescent anisotropy experiments. 
The anisotropy values of BSA are 0.06 ± 0.005 and 0.15 ± 0.002 for the free and BSA loaded 
cubosomes, respectively. Moreover, fluorescence quenching measurements of BSA included 
in cubosomes (dialyzed sample, black triangles in Fig. 1C) clearly show a decrease of the 
BSA quenching. The protein is therefore less accessible to the quencher when compared to 
the un-dialyzed and free protein samples (black and white circles, respectively in Fig. 1C). 
BSA release from cubosomes was subsequently investigated by fluorescence experiments as 
discussed above. As shown in Fig. 1D (black circles; left axis) only about 22 % BSA was 
released up to 2 days, and a slow release occurs within one week (60 % of the loaded BSA). 
Furthermore, the size of cubosomes does not increase during the release, as shown in Fig. 1D 
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(diamonds, right axis), confirming that the protein is able to diffuse out from the aqueous 
channels of the cubosomes without aggregation. 
 
Assessment of cubosome toxicity on human kidney cells 
The potential toxicity of empty cubosomes as function of concentration and incubation time 
was evaluated using the standard MTT assay for cell viability on HK2 cells, which are 
routinely used for PT cell toxicology screening. A significant decrease in cell viability was 
observed after 1h incubation with empty cubosomes of concentrations of 200µg/ml (viability 
25 ± 13.7%) and 500µg/ml (4 ± 4%), whereas viability was not significantly affected at 
concentrations of 100µg/ml and 150µg/ml (viability 97 ± 3% and 84 ± 3%, respectively) 
(Table 2; Suppl. Fig. 1A).  
Table 2. Viability of HK2 cells after incubation with various concentrations of empty cubosomes for 1h at 37°C. 
 Cubosome concentration (µg/ml) 
 0 100 150 200 500 
Viability (%) 100 ± 2.6 97 ± 2.6 84 ± 2.9 25 ± 13.7 *** 3.7 ± 4.1 *** 
3 wells per condition in 3 independent experiments. *** p<0.001 compared to control (0) 
 
A time-course experiment with empty cubosomes exhibiting the highest-tested concentration 
that did not have significant impact on cell viability (150 µg/ml) did not show any significant 
changes in cell viability upon exposure up to 60 min (Table 3).  
Table 3. Viability of HK2 cells after time course incubation with 150µg/ml cubosomes loaded with 0.1mg/ml BSA. 
 Incubation time (min) 
 0 5 15 60 
Viability (%) 100 ± 2.6 94 ± 1.6 95 ± 1.3 92 ± 0.7 
3 wells per condition in 3 independent experiments. No significant differences. 
 
As BSA can slowly diffuse out of the cubic phase, the effective BSA concentration was 
independently confirmed using a standard BCA protein quantification kit (Suppl. Fig. 1B).  
Based on the results obtained in the experiments above, a final working cubosome 
concentration of 150 µg/ml, loaded with 100µg/ml BSA (to avoid cell overloading) was 
established and used for all experiments, unless otherwise indicated. 
 
Uptake and processing of BSA-loaded cubosomes in low-endocytic capacity cells  
Initially, the internalization and degradation of BSA-loaded cubosomes in HK2 cells, 
characterized by a relatively low endocytic capacity 20, was monitored. Following a pulse of 
1h at 4°C, the localization of BSA was analyzed at different time points by confocal 
microscopy (Fig. 2A) and the Alexa Fluor® 488 BSA signal was quantified using a 




Figure 2. BSA degradation in HK2 cell monolayers 
HK2 cells were cultured on chamber slides, pulsed with 0.1mg/ml Alexa Fluor® BSA for 1h at 4°C, either pure or loaded in 
0.15mg/ml cubosomes, and degradation was monitored (A) for the indicated time points. Fluorescence signal of pure BSA is 
cleared after 60min degradation while the BSA signal from cubosomes remains strong. (B) After cell lysis, fluorescence 
signal for indicated time points was quantified relative to the Albumin control, presented in %. Significant decrease of 
fluorescence signal could be observed for both conditions (BSA and cubosomes) after 30 and 60min. Cubosomes show a 
significantly stronger signal at all times compared to pure BSA. *# p<0.05, ** p<0.01, ### p<0.001 with * vs. control and # 
vs. Albumin. 
Exposure of HK2 cells to Alexa Fluor® 488-BSA alone led to rapid internalization followed 
by sizeable degradation already at 15 min and an almost complete loss of signal after 1h (Fig. 
2A upper row). The same incubation with Alexa Fluor® 488-BSA loaded into cubosomes 
resulted in a much stronger fluorescence signal which could be detected up to 60 min after the 
pulse (Fig. 2A, lower row). These observations were supported by the quantification of the 
residual signal of Alexa-488 BSA (Fig. 2B; Table 4).  
Table 4. Impact of empty cubosomes on endocytosis in HK2 cells (%) after incubation with either pure bovine serum albumin 
(BSA, 0.1mg/ml), BSA co-incubated with empty (0.15mg/ml) cubosomes (BSA+Cubos), or 0.1mg/ml BSA loaded into 
0.15mg/ml cubosomes (Cubos). 
 5min 15min 60min 
BSA  36 ± 20 18 ± 6** 9 ± 3* 
BSA+Cubos 42 ± 1 32 ± 21 15 ± 8 
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loaded Cubos 173 ± 25$ 115 ± 25#, $ 117 ± 23#, $$ 
3 wells per condition in 3 independent experiments. *#$ p<0.05, **$$ p<0.01  
(*BSA vs control, # cubosomes vs control, $ BSA vs. cubosomes, BSA+Cubos vs. BSA not significant 
 
A significant decrease of the internalized BSA was already observed after 15min, whereas 
only approximately 10% of residual signal was detected after 1 hour. In contrast, the initial 
signal obtained for Alexa Fluor® 488-BSA-loaded cubosome incubation was 4-fold increased 
(173 ± 25%, p<0.05) compared to the pure Alexa Fluor® 488-BSA uptake (36 ± 20%). 
Despite a decrease after 15min and 60min, a significant residual signal persisted at 1 hour, 
amounting to a 10-fold higher intensity than that obtained for Alexa Fluor® 488-BSA alone. 
Confocal Z-stack analysis confirmed the internalization of the Alexa Fluor® 488-BSA cargo 
in HK2 cells (data not shown).  
To rule out the possibility that the presence of cubosomes per se might affect the endocytic 
uptake, the uptake in HK2 cells of Alexa Fluor® 488-BSA alone (0.1 mg/ml) or combined 
with empty cubosomes was compared. The presence of empty cubosomes did not affect the 
uptake of BSA in these monolayers, and the signal was significantly decreased after 60 min in 
both conditions (Suppl. Fig. 2).  
Table 5. Analysis of co-localization (%) of BSA with endo-lysosomal markers (Rab5, Rab7, CatD) after incubation of HK2 
cells with either pure BSA (0.1mg/ml, BSA) or BSA loaded into 0.15mg/ml cubosomes (Cubos).  
Incubation 15 min 60 min 
Marker Rab5 Rab7 CatD 
BSA 72 ± 3.2 20.5 ± 1.6 56.9 ± 4 
Cubos 48.8 ± 2.7 ** 70.4 ± 3.6 *** 19.5 ± 2.5 *** 
All cells of 5 images per staining in 3 independent experiments. ** p<0.01, *** p<0.001 vs. control. 
 
Immunofluorescent staining with endo-lysosomal markers (Fig. 3; Table 5) substantiated the 
co-localization of internalized Alexa Fluor® 488-BSA in Rab5-positive early endosomes (72 
± 3%) after 15min, and with cathepsin D-positive lysosomes (57 ± 4%) and the late 




Figure 3. Intracellular locailzation of BSA 
Bafilomycin treated, methanol fixed monolayers were stained for endosomal (Rab5, Rab7) and lysosomal markers (CatD). 
(A) Confocal analysis shows co-localization between pure BSA and both markers (Rab5, CatD) after 15 resp. 60min 
degradation, while cubosomes do only co-localize partially with Rab7 and CatD after 60min. (scale bar 25µm) (B) 
Colocalization analysis shows a shift of cubosome signal towards the late endosomes after 60min when naturally BSA is 
already found in the degrading lysosomes. ** p<0.01, ***p<0.001 BSA vs Cubosomes at corresponding time points. 
In contrast, Alexa Fluor® 488-BSA delivered within cubosomes showed some co-localization 
(49 ± 3%) with early endosomes after 15min, and a robust co-localization (70 ± 4%) with late 
endosomes contrasting with a lower signal (20 ± 3%) with lysosomes after 60 min (Fig. 3A 
lower row).  
Taken together, these data suggest that, compared with direct incubation of BSA alone, 
delivery of BSA within cubosomes is manifested by a higher uptake, a distinct intracellular 




Subcellular distribution of BSA 
Electron microscopy was used to substantiate the subcellular distribution of gold-labelled 
BSA in HK2 cells (Fig. 4).  
 
Figure 4. EM Analysis after incubation with cubosomes loaded with BSA-gold 
Further localization analysis was performed using transmission electron microscopy with GA-fixed cell pellets. (A) Empty 
cubosome, (B) BSA-Gold loaded cubosome. The localization of pure BSA-Gold particles in endosomes (C) as well as 
lysosomes (D) was shown. However, Cubosomes loaded with BSA-Gold were mostly found intracellularly (E, Scale bar 
250µm) and started to show in endosome-like structures after 60min. (E, F scale bar 500µm)  
Empty cubosomes and cubosomes loaded with Alexa Fluor® 488-BSA were first detected 
separately and extracellularly for technical adjustments, as shown on representative images in 
Fig. 4 A/B. Under standard conditions (incubation of HK2 cells with pure BSA-gold), BSA 
was detected after 5 min in endosomes (simple membrane-surrounded structures; Fig. 4C), 
and after 60 min in lysosomes (multi-layered structures; Fig. 4D). Following incubation with 
cubosomes containing gold-labelled BSA, the gold particles were mostly detected free in the 
cytosol after 5 min (Fig. 4E) and rarely in the lysosomes, but rather in the endosomes after 60 
min (Fig. 4F-G). While endosomes show a simple membrane structure, lysosomes can be 
distinctively identified through their characteristic multi-layered membranes (Fig. 4C-G). 
These observations support the distinct processing and subcellular localization of the cargo 
internalized through cubosomes.  
 
Uptake and processing of BSA-loaded cubosomes in OK cells 
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In order to assess the potential effect of the variable endocytic rate at baseline, we performed 
similar uptake experiments in OK cells, which are characterized by a high basal level of 
receptor-mediated endocytosis (Prange, 2016). The OK cell monolayers were incubated with 
either Alexa Fluor® 488-BSA (100 µg/ml) alone or with BSA loaded into 150 µg/ml 
cubosomes (Suppl. Fig 3A/B; Table 6).  
Table 6. Comparison of the impact of 0.15mg/ml cubosomes on endocytosis of 0.1mg/ml BSA (ng/µg protein) in different cell 
lines: low endocytic cell line (HK2), high endocytic cell line (OK) and primary cells from different genetic backgrounds. 
Values are normalized to 15min time point of HK2. 
Cell line Substrate Time point (min) Uptake (% rel. to HK2) 
HK2 
BSA 
15 100.00 ± 26.67 
60 14.09 ± 3.71 ** 
Cubos 
15 185.18 ± 15.28 # 
60 48.95 ± 20.56 * 
OK 
BSA 
15 185.84 ± 0.37 
60 33.69 ± 4.25 *** 
Cubos 
15 198.91 ± 35.45 




15 665.42 ± 56.1 
60 260.25 ± 21.55 * 
Cubos 
15 1597.2 ± 68.99 ### 




15 405.6 ± 53.13 
60 190.69 ± 10.34 ** 
Cubos 
15 1571.7 ± 267.57 ## 
60 351.49 ± 71.26 ** 
3 wells per condition in 3 independent experiments. *# p<0.05, **## p<0.01, ***### p<0.001 with * compared to 15min and # BSA 
vs cubos. 
 
Representative images are shown in Fig. 3A.The initial uptake values (15 min) of pure BSA 
vs. BSA loaded cubosomes are similar in OK cells (1.07 fold increase from BSA to 
cubosomes), contrasting with the almost doubled uptake for BSA in cubosomes observed in 
the HK2 cells (185 ± 15% uptake with cubosomes, relative to BSA). However, after 60 min, 
the degradation of BSA in cubosomes is similarly reduced under control conditions (albumin 
degradation) in OK (63.5 ± 5%) as it is in HK cells (49 ± 21%). Furthermore, albumin levels 
remain significantly increased after 60min with cubosome treatment compared to the albumin 
treatment to the same extend within the OK cell line as is the case for the HK2 cell line 
(Suppl. Fig. 3B; Table 6). In comparison to both, an increase can be observed for the 
incubation with cubosomes compared to BSA in mouse primary cells (mPTC) for both 
wildtype (2-fold) and KO (3-fold) after 15min (240 ± 10% for WT, resp. 236 ± 40% for KO). 
The later time point did not reveal any significant difference between WT and KO (p > 0.05). 
 
Uptake and processing of BSA-loaded cubosomes in proximal tubule cells and intact 
kidneys from Clcn5 mice 
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The experiments performed in different cell systems indicated a distinct intracellular routing 
and delayed degradation when using cubosomes to deliver BSA in PT cells. In order to test 
the potential relevance for such delivery in clinical situations, we conducted experiments 
using the Clnc5 KO model, a faithful model of Dent disease characterized by defective 
receptor-mediated endocytosis causing a generalized loss of solutes in the urine 14, 16.  
The uptake of pure Alexa Fluor® 488-BSA and of BSA in cubosomes was compared in 
highly differentiated mPTCs obtained from Clcn5 KO and WT kidneys (Fig. 5, Table 6).  
 
Figure 5. Application of cubosomes in an endocytosis-deficient cell model 
Self-dissected primary PT cells were generated and grown to monolayers as previously described 30. The clcn5 KO mouse 
model was used as an endocytosis-deficient model and compared to WT. Monolayers were incubated with either 0.1mg/ml 
pure Alexa-488 BSA or 0.15mg/ml cubosomes containing 0.1mg/ml Alexa-488 BSA for 15min. Uptake was monitored (scale 
bar 20µm, A) and quantified (B). Clcn5 deficient cells show a clear decrease in the uptake of pure BSA compared to WT 
cells, but the application of cubosomes seems to overcome this deficiency and restores the uptake. * p<0.05, ** p<0.01, 
***p<0.001 
As expected, the uptake of 0.1mg/ml pure BSA was significantly reduced in the Clcn5 KO as 
compared with WT mPTCs (405± 53% vs. 665 ± 56%., respectively, p < 0.05). The delivery 
of BSA in cubosomes enhanced the uptake in both conditions, with a 2.5-fold increase in WT 
cells vs a 4-fold increase in KO cells (Suppl. Fig. 3B). Importantly, the delivery of BSA with 
cubosomes enabled to increase the albumin uptake of KO cells up to the same level as that 
observed for WT cells (1577 ± 67% resp. to 1571 ± 268%).  
Intravital multiphoton microscopy has emerged in the last decade as a powerful tool to study 
dynamic physiological processes in vivo. With this technique it is possible to follow the 
filtration, uptake and handling of solutes in real time in the intact kidney 25. To assess the 
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handling of cubosomes in vivo they were injected through a jugular vein catheter into either 
WT or clcn5y/- mice while simultaneously imaging the kidney outer cortex (Suppl. videos). As 
can be seen in the videos, BSA was visible in the vasculature immediately post-injection, and 
after 20 seconds it appeared in the PT brush border, consistent with rapid filtration. Shortly 
afterwards, BSA signal was localized to PT endosomes, and then subsequently to lysosomes. 
Quantification of signal intensity over time revealed that uptake of cubosome-BSA was 
strikingly higher than with BSA alone (approximately 10 fold higher) (Fig. 6A/B).  
 
Figure 6. In vivo uptake quantification. 
250µl of 0.1mg/ml pure fluorescently-labeled BSA or 0.15mg/ml cubosome solution (containing 0.1mg/ml fluorescently-
labeled BSA) was injected via a cannulated internal jugular vein into WT and clcn5 KO mice. The left kidney was 
externalized and real-time imaging performed with multiphoton microscopy. (A) Quantification of fluorescent BSA signal 
intensity in proximal tubules over time revealed that uptake was much higher when injected in cubosomes, compared to BSA 
alone, in both wildtype and CLC5y/- mice. The uptake of BSA in cubosomes in CLC5y/- mice even exceeded that in wildtype 
mice injected with BSA alone. (B) Representative images are depicted of BSA uptake 10 minutes post-injection (scale bar = 
100 µm). 
As expected, uptake of BSA alone was much lower in clcn5y/- mice. However, uptake of 
cubosome-BSA was substantially increased in both animals, WT and KO, and final signal 
intensities of cubosome-BSA treated KO animals were even higher than those of BSA alone 
in WT mice. To confirm the uptake of cubosome-BSA into lysosomes, mice were co-injected 
with the established lysosomal fluorescent marker Lysotracker, which was observed to co-





The utilization of cubosomes as protein carriers requires a comprehensive understanding and 
control of their physico-chemical properties. In this investigation, empty cubosomes, as well 
as cubosomes loaded with BSA were prepared following a state-of-the-art, bottom-up 
approach 21. SAXS was used to systematically investigate the particle design space of MO-
based cubic structure. 
Cubosomes can generally entrap proteins 13, 31, 32 and release them after a certain time 33. The 
encapsulation efficiency depends on the method of preparation used, on the lipid type and the 
concentration 9, 13. In our approach, following dialysis treatment of the formulation, 20 % of 
the protein, corresponding to 0.1 mg/mL of BSA is stably entrapped in the cubosome. The 
location of the protein in the aqueous channels of the cubosomes was determined by 
anisotropy and quenching fluorescence measurements. Fluorescence quenching was used to 
obtain information about the position of the fluorophore in the lipid bilayer by studying the 
accessibility of the quencher (I-) to the fluorophore and the efficiency of quenching 34. 
Fluorescence measurements clearly show a decrease of the quenching of the protein: BSA in 
the dialyzed sample is therefore located in the aqueous channels of the cubosomes, and the 
fraction of BSA accessible to the quencher decreases. Moreover, an increase of the anisotropy 
value confirms that the protein is located in a structure with a reduced mobility 21.  
As discussed above, cubosomes are able to entrap BSA and prevent its spontaneous burst 
release with time. Small drugs are known to release virtually immediately from cubosomes 35 
by virtue of the high surface area-to-volume ratio of submicron particles However, BSA, 
being a relatively large and somewhat surface active protein appears to be retained in the 
cubosomes for a period of days, slowly leaking from the matrix into the surrounding solution. 
The release behavior therefore confirms the ability of cubosomes to entrap the protein and 
avoid its fast release. 
We used various types of PT cell systems to investigate the potential toxicity of the 
cubosomes and to monitor the internalization and intracellular distribution of the cargo at the 
light and electron microscopy levels. The handling of BSA-loaded monoolein-based 
cubosomes was tested on well-established renal PT cells, characterized by variable levels of 
differentiation ranging from HK2 cells (low endocytic activity), OK cells (intermediate 
endocytic activity) and mPTC (primary cultures, high endocytic activity 20). The effective 
working concentration (0.15mg/ml cubosomes carrying 0.1mg/ml Alexa Fluor® 488-BSA) 
did not affect cell viability and corresponded to the maximal amount of BSA technically 
possible to load into the cubosomes (part of the originally loaded BSA diffuses out of the 
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cubic phase during the production). Hence, the concentration of albumin within the cubosome 
solution is slightly below the physiological one (2.7 - 3.5 mg/dl) but leaves room for technical 
optimization depending on the particular cargo.  
Pulse-chase experiments in PT cells showed delayed degradation of the Alexa Fluor® 488-
BSA signal when applied in cubosomes, compared with incubation with BSA alone. A 
possible explanation might be that cubosomes bypass the endocytic receptors responsible for 
the uptake and subsequently internalization and processing in the endolysosome compartment. 
No specific binding of the cubosomes to the megalin receptor is expected: even after short 
incubation, no membrane associated fluorescence signal could be observed with the 
cubosomes. The pathways potentially involved in cubosome internalization include channels 
and other, non-receptor mediated forms of endocytosis such as pinocytosis or phagocytosis. 
 We observed that cubosomes are able to increase the uptake of BSA in HK2 cells and mPTCs 
but not in OK cells. Reasons for these differences may include variable differentiation levels 
in the cells, resulting in low expression levels of receptors and/or transport systems located in 
the apical membrane 20. 
Confirmation that BSA-loaded cubosomes are taken up and processed in the endo-lysosomal 
compartment was provided by z-stack analysis, TEM and co-localization studies with 
endolysosomal markers in PT cells. Compared to pure BSA, which mostly co-localized under 
Bafilomycin-treated conditions in early endosomes after 15 min, only very few endosomes 
co-localized with cubosome-delivered BSA at this stage. While pure BSA was mostly located 
into lysosomes (marker:Rab7 and CatD) at 60min, only minimal colocalization was obtained 
for cubosome delivered BSA. These differences could be due to the distinct entry pathway(s) 
of cubosomes - bypassing the receptors and the potential re-arrangement of cubosome lipids 
into the cellular membranes upon entry into the cell. The cubosome membrane shape is by 
itself active, lowering the free energy required to promote fusion and pore formation with the 
endosomal membrane and leading to an efficient escape 5. Hence, one might describe this 
observation as endosomal escape 36, which could be further supported by the fact that 
metabolic inhibition as well as lysosomal blocking with Bafilomycin did not affect the 
degradation of Alexa Fluor® 488-BSA when delivered within the cubosomes. Further studies 
with tagged lipid entities would be needed to substantiate that hypothesis. 
Since the cubosomes appear to bypass the megalin and cubilin receptors for PT cell 
internalization, they could be used to internalize cargo in genetic disorders affecting receptor-
mediated endocytosis. The latter hypothesis was tested in vitro and in vivo, using the 
described mouse model of Dent’s disease – an example of defective endocytosis. Whereas the 
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uptake of BSA alone was much lower in clcn5y/- primary cells and mice, as expected, the 
uptake of cubosome-BSA was increased in both cases, and was even higher than that of BSA 
alone in WT mice. These data support that cubosomes present a potent new system to deliver 
cargo across cell membranes, even when endocytic receptors are genetically deficient.  
In summary, the results presented support the use of cubosomes as a delivery system able to 
overcome the low endocytic uptake in diseased epithelial cells. They represent a promising 
approach to treat proximal tubule dysfunctions and, more generally, defects in highly 
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